Table of Contents:
Fourth Quarter Financial Results
Abbott Labs, a major player in the global pharmaceutical sector, reported revenues of approximately 11 billion dollars in the fourth quarter of 2024, an increase of 7.2% compared to the same period of the previous year. Although the results were slightly lower than the expectations of investors, who expected revenues of 11.03 billion, the company still achieved the set objectives, demonstrating
a solid performance in the market.
Analysis of EPS and annual forecasts
In the fourth quarter, Abbott’s GAAP diluted EPS was $5.27, while adjusted diluted EPS came in at $1.34, in line with analysts’ estimates. Looking at the full year, revenues reached 42 billion dollars, an increase of 4.6%. GAAP diluted EPS for the year was $7.64, while adjusted diluted EPS reached $4.67, both at the upper limit of the initial forecasts made
in January.
Future Perspectives and CEO Statements
Abbott provided positive guidance for the future, forecasting organic sales growth for 2025 of between 7.5% and 8.5%. In addition, the company expects an adjusted operating margin of between 23.5% and 24% of sales, with an expected adjusted diluted profit of between 5.05 and 5.25 dollars. Robert B. Ford, president and CEO of Abbott, commented: “We ended the year with very strong momentum. Sales growth and earnings per share growth in the fourth quarter were the highest in the year.” These statements highlight the company’s confidence in its business model and in its ability to face future challenges
.
Impact on the stock market
In a context of growth for Abbott, it is also interesting to note the recent buyback transactions by Eni, which purchased more than 3.5 million treasury shares in the period from 13 to, representing 0.11% of the share capital. This purchase, with a cost of 50 million euros, led Eni to hold a total of 3.66% of the share capital. These transactions have a significant impact on the stock market, highlighting investor confidence in the growth potential of the companies involved
.
